Conduit Pharmaceuticals to rename as CDT Equity Inc.

Conduit Pharmaceuticals Inc. is changing its name to CDT Equity Inc. to reflect its evolved strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company will leverage artificial intelligence and solid-form chemistry to drive its development efforts.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) has announced its intention to change its name to CDT Equity Inc. The rebranding reflects the company's evolution into a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [1][2].

Originally established as Conduit Pharmaceuticals, the company has expanded its scope to leverage artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments. CDT Equity Inc. aims to unlock the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies despite strong Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at its Cambridge facility, the company has successfully extended the patent life of certain drugs by up to 20 years [1][2].

The company's current pipeline includes candidates targeting inflammatory and autoimmune disorders, idiopathic male infertility, dermatology, and animal health. CDT Equity Inc. has collaborated with Sarborg to apply proprietary algorithms utilizing AI-powered disease mapping, which has informed two new combination patent filings and guided pre-clinical in-vitro models exploring new indications [1][2].

Additionally, CDT Equity Inc. has partnered with Manoira to expand its drug portfolio into the animal health market in a cost-efficient manner. This collaboration allows the company to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its portfolio across multiple species while retaining 100% ownership of all data and intellectual property generated for human applications [1][2].

The Board of CDT Equity Inc. is also evaluating a cryptocurrency treasury reserve strategy, working with consultants to best advise on this novel market, which has seen significant recent activity and success for respective stakeholders. Long-term exposure to digital assets can present both strategic and financial benefits as part of a diversified capital management approach [1][2].

"Operating with a lean, disease-agnostic model, CDT Equity Inc. prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies," said Dr. Andrew Regan, Chief Executive. "Looking ahead, we are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation" [1][2].

This press release contains certain forward-looking statements within the meaning of the federal securities laws [1][2].

References:
[1] https://finance.yahoo.com/news/conduit-change-name-cdt-equity-123000903.html
[2] https://www.morningstar.com/news/globe-newswire/9506342/conduit-to-change-name-to-cdt-equity-inc